Hanmi Pharmaceutical launches prescription availability for GLP-1 obesity drug Efpe

Efpe will be available at South Korean medical facilities on 29 October 2026, 22 days following regulatory approval.

Vera Castillo

Food is Medicine Writer

Share on X

Stands on 3 placed sources from 2 publishers.

New obesity drug available at South Korean hospitals AI illustrationhow this picture was made

Hanmi Pharmaceutical began prescription availability for its domestic GLP-1 obesity drug Efpe on the 29th.^[1] The launch occurs 22 days after the drug received regulatory approval. Prescriptions will be offered through South Korean medical facilities.^[2] Hanmi Pharmaceutical has stated it aims to establish a three-way market share structure in the domestic GLP-1 obesity drug market. The market has an annual value of 2 trillion KRW.^[3]

Proof3 sources · 2 publishers · signed

What this stands on

Hanmi Pharmaceutical began prescription availability for its domestic GLP-1 obesity drug Efpe on the 29th. · The Kyunghyang ShinmunSouth Korea
Hanmi Pharmaceutical will begin prescription of its GLP-1 obesity drug Efpe at South Korean medical facilities on 29th, 22 days after receiving regulatory approval. · 동아일보
Hanmi Pharmaceutical aims to establish a three-way market share structure in the 2 trillion KRW annual domestic GLP-1 obesity drug market. · The Kyunghyang ShinmunSouth Korea

The one we could place publishes from South Korea. 1 could not be placed by their address. None is an official body: that part stands on reporting, not on the underlying document or transcript.